Smith & Nephew plc
SNNUF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$12.9B
Close$
$10.72
18.9% downside
Current Fair Value
18.9% downsideOvervalued by 18.9% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $12.90 Billion |
|---|---|
| Enterprise Value | $15.93 Billion |
| Annual dividend | $0.39 |
| Dividend yield | 2.90% |
| Earnings per Share | $0.74 |
| Beta | 0.54 |
| Outstanding Shares | 849,324,845 |
Return
| Return on Equity | 21.77% |
|---|---|
| Return on Assets | 10.24% |
| Return on Invested Capital | 19.89% |
Valuation & Multiples
| P/E Ratio | 17.76 |
|---|---|
| PEG | 713.96 |
| Price to Sales | 0.94 |
| Price to Book Ratio | 2.2 |
| Enterprise Value to Revenue | 1.3 |
| Enterprise Value to EBIT | 8.94 |
| Enterprise Value to Net Income | 14 |
| Total Debt to Enterprise | 0.24 |
| Debt to Equity | 0.73 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$0.47
Consensus analyst estimateRevenue Estimate
$3.46 B
Consensus analyst estimateNext Earnings Call
Expected Date
February 23, 2027
EPS Estimate
$0.60
Consensus analyst estimateRevenue Estimate
$3.32 B
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Smith & Nephew plc
18,362 employees
CEO: Roland Diggelmann
Smith & Nephew plc, along with its subsidiaries, operates globally as a developer, manufacturer, marketer, and seller of medical technology. Its orthopaedic division offers knee implants for replacement procedures and hip implants for jo...